Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone

References

• Carmen B, Angeles M, Ana M, María AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99:811–28.
   PubMed Web of Science ®Google Scholar
• Baros AM, Latham PK, Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist?. Alcohol Clin Exp Res 2008; 32:771–6.
   PubMed Web of Science ®Google Scholar
• Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. Ann NY Acad Sci 2011; 1216:144–66.
   PubMed Web of Science ®Google Scholar
• Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006; 101:491–503.
   PubMed Web of Science ®Google Scholar
• Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 2002; 97:1241–9.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr. Opin. Psych 2010; 23:210–4.
   PubMed Web of Science ®Google Scholar
• Greenfield SF, Pettinati HM, O’Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res 2010; 34:1803–12.
   PubMed Web of Science ®Google Scholar
• Cousins SJ, Radfar SR, Crèvecoeur-MacPhail D, Ang A, Darfler K, Rawson R. Predictors of continued use of extended-released naltrexone (XR-NTX) for opioid-dependence: an analysis of heroin and non-heroin opioid users in Los Angeles County. J Subst Abuse Treat 2016; 63:66–71.
   PubMed Web of Science ®Google Scholar
• Ahamad K, Milloy M, Nguyen P, et al. Factors associated with willingness to take extended release naltrexone among injection drug users. Addict Sci Clin Pract 2015; 10:1–6.
   Google Scholar
• Ling W, Mooney L, Wu L-T. Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin N Am 2012; 35:297–308.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Vivitrex study group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293:1617–25.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004: 28:1356–61.
   PubMed Web of Science ®Google Scholar
• Tidey JW, Monti PM, Rohsenow DJ, et al. Moderators of naltrexone's effects on drinking urge and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 2008; 32: 58–66.
   PubMed Web of Science ®Google Scholar
• Setiawan E, Pihl RO, Cox SM, et al. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res 2011; 35:1134–41.
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM. COMBINE study research group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003–17.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Krishnan-Sarin S, Farren C, O’Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol 2000; 20: 69–76.
   PubMed Web of Science ®Google Scholar
• Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict 2008; 17:463–8.
   PubMed Web of Science ®Google Scholar
• Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacol 2001; 154:397–402.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Kampman KM, Lynch KG, et al. Gender differences with high-dose naltrexone in the patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008; 34:378–90.
   PubMed Web of Science ®Google Scholar
• Hulse GK. Improving clinical outcomes for naltrexone as a management of problem alcohol use. Br J Clin Pharmacol 2013; 76:632–41.
   PubMed Web of Science ®Google Scholar
• Mark TL, Kranzler HR, Xue S. Understanding US addiction physicians’ low rate of naltrexone prescription. Drug Alcohol Depend 2003; 71:219–28.
   PubMed Web of Science ®Google Scholar
• Cousins SJ, Crevecoeur-MacPhail D, Denering D, et al. A demonstration project implementing extended-release naltrexone in Los Angeles County. Subst Abus 2016; 37:54–62.
   PubMed Web of Science ®Google Scholar
• SAPC. (The Los Angeles County Department of Public Health Substance Abuse Prevention and Control). How to access Vivitrol for clients of SAPC-contracted treatment programs, 2010. http://publichealth.lacounty.gov/sapc/FactSheet/VivitrolFactSheet.pdf (accessed December 9, 2015).
   Google Scholar
• Crèvecoeur-MacPhail D, Ransom L, Myers AC, Rawson R. Inside the black box: measuring addiction treatment services and their relation to outcomes. J Psychoactive Drugs SARC Suppl 2010; 6:269–76.
   PubMedGoogle Scholar
• Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn alcohol craving scale. Alcohol Clin Exp Res 1999; 23:1289–95.
   PubMed Web of Science ®Google Scholar
• Rawson RA, Gonzales R, Brecht ML, Crèvecoeur-MacPhail D, Hemberg J. Evaluation of the California Outcomes Measurement System (CalOMS): final report. Los Angeles, CA: UCLA Integrated Substance Abuse Programs (prepared for the Department of Alcohol and Drug Programs California Health and Human Services Agency), 2008.
   Google Scholar
• Brady KT, Randall CL. Gender differences in substance use disorders. Psych Clin N Am 1999; 22(2):241–52.
   PubMed Web of Science ®Google Scholar
• US DHHS SAMHSA. U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set Admissions (TEDS-A) Concatenated 1992 to 2012. 2014. Ann Arbor MI: Inter-university Consortium for Political and Social Research 2014–01–27. http://www.icpsr.umich.edu/icpsrweb/SAMHDA/studies/25221/version/7 (accessed December 9, 2015).
   Google Scholar
• Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010; 69:578–92.
   PubMed Web of Science ®Google Scholar
• Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind placebo-controlled laboratory study. Neuropsychopharmacol 2015; 40(10): 2347–56.
   Web of Science ®Google Scholar
• Boeri MW, Harbry L, Gibson D. A qualitative exploration of trajectories among suburban users of methamphetamine. JEQR 2009; 3:139–51.
   Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid dependent individuals. Am J Addict 2008; 17:396–401.
   PubMed Web of Science ®Google Scholar